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ABSTRACT 
The goal of this project is to design and synthesize compounds that can potentially target 
breast cancer cells selectively, and can cause specific DNA-damage in these tumor cells. The 
molecules that will be synthesized will consist of 3 components: (a) a component known to 
selectively methylate the N3-position of adenine in A/T-rich regions of DNA, (b) a component 
known to target breast cancer cells due to its specific binding to the estrogen receptors (ER) that 
are over expressed in early stage breast cancer cells, and, (c) a variable linker component, that 
connects the above two functional components in such a way that the desired properties (DNA-
methylation and cell-targeting) are optimized. The specific kind of DNA-damage, the N3-
methyladenine adduct, is one that has been shown to cause only cell-death, and not cause 
mutations. The cell-targeting component chosen is estradiol, which has been often used to 
deliver agents to breast cancer cells. This thesis discusses the design of these compounds, and the 
synthetic strategy that has been developed for the preparation of these compounds. The progress 
towards the synthesis of one of these compounds is also described. Understanding how to target 
breast cancer cells preferentially, and how to cause only the kind of DNA-damage that results in 
cell-death, will aid in the design of new drugs that can destroy breast tumors while minimizing 
unwanted side-effects, and eliminating the incidence of secondary cancers. 
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INTRODUCTION 
 
 Some cancer chemotherapy drugs such as mechlorethamine, busulfan, and dacarbazine 
are DNA-alkylating compounds1.  Such alkylating compounds usually damage DNA extensively 
at multiple sites leading to the death of the cells.  Cancer chemotherapy drugs attack all cells in 
the body, both normal and cancerous, and damage DNA.  Most normal cells survive the DNA 
damage that occurs as a result of the cancer chemotherapy drugs because repair enzymes have 
time to mend the damage on DNA.  On the other hand, in cancerous cells, the repair enzymes are 
either not functioning well, or they are unable to fix the damage before DNA replication is 
initiated in these rapidly dividing cells. This DNA damage that persists during cell-division in 
these cells triggers signals that result in the death of these cells. Normal cells that are rapidly 
dividing, for example, hair cells and cells that line the stomach, are also killed by this process, 
since in these cells too, the DNA-damage is not repaired before cell-division is initiated.  This is 
why people undergoing cancer chemotherapy treatment with alkylating drugs have side effects 
such as hair loss and gastric irritation1. 
 Damage at various sites on DNA can result in different biological outcomes depending 
upon the site of alkylation.  Alkylation at some sites cause the death of the cell, which is the 
desired outcome in a cancer drug.  Alkylation at other sites can result in mutations, which are 
believed to be a cause of secondary cancers.  Thus, these secondary cancers are caused by the 
DNA-alkylating drug used to treat the primary cancer, and the drugs used to treat the primary 
cancer cannot be used to treat the new cancer.  DNA alkylation at certain sites can cause both 
cell-death and mutations, while damage at some sites appear to have no biological consequence. 
Alkylation at sites that do not cause cell-toxicity are a waste of the chemotherapy drug and will 
necessitate the use of higher doses for the treatment to be effective, which also leads to an 
increase in unwanted side effects. 
 An ideal cancer drug would be one that targets only cancerous cells, and one that 
causes damage only at those sites on the DNA in these cells that results in cell-death.  Such ideal 
drugs would exhibit improved efficiency (therefore requiring lower dosage), minimize side-
effects, and eliminate the incidence of secondary cancers. 
 This thesis describes our efforts to design and make compounds that address some of 
the issues discussed above.  We are attempting to make compounds that could potentially target 
breast cancer cells, and cause only the specific kind of DNA-damage in those cells that have 
been shown, in literature, to cause only cell toxicity (without causing mutations).  The results 
from this study can aid in the design of improved cancer chemotherapy drugs.  
 
 
 
 
 
 
 
 
 
 
BACKGROUND AND SIGNIFICANCE 
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Background: 
 The goal of this research is to make a compound that will target a specific kind of cell 
(breast cancer) and cause specific damage to DNA in that cell that will result only in cell toxicity 
and not in mutations.  The design of compounds that can target and react with specific sites on 
DNA requires a good understanding of DNA structure and accessibility. 
 DNA (deoxyribose nucleic acid) is a double helix that is made up of a sugar-phosphate 
backbone on the outside and the interior is a helix of nitrogenous base pairs, which are holding 
the two strands together through hydrogen bonding (Figure 1).  There are four bases adenine (A), 
thymine (T), guanine (G), and cytosine (C), each of which can pair only to a specific base, 
adenine pairs with thymine and guanine pairs with cytosine.  The base-pairing of the two strands 
of DNA results in the formation of two grooves of DNA, the major groove and the minor groove 
(see Figure 1).  The major groove is wide and easy to access, and many proteins and enzymes 
interact with the major groove.  The minor groove is deep, narrow and difficult to access.  
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Major Groove 
Minor Groove 
Figure 1.  Structure of DNA showing the major and minor grooves, and base-pairing. 
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 Figure 2 shows the top view of an AT and GC base pair, and the orientation of various 
sites that results from the base-pairing.  In the AT base pair, the sites that lie in the major groove 
are N7 and N6 of adenine and O4 thymine .  The N3 of adenine and O2 of thymine lie in the 
minor groove.  In the GC base pair, the sites that lie in the major groove are N7 and O6 of 
guanine and N4 of cytosine.  The sites that lie in the minor groove for the GC base pair are the 
N3 and N2 of guanine and O2 of cytosine.  
 The arrows shown in Figure 2 point to sites that can get damaged by DNA-alkylating 
agents.  Damage at different sites can lead to different biological consequences.  Damage at 
certain sites can lead to cell-death, while damage to other sites can lead to mutations.  N7 
guanine is easily accessible and the most reactive site on the DNA bases.  The N7-methylguanine 
adduct has been shown to be non-cytotoxic and non-mutagenic2.  The O6-methylguanine adduct 
is both cytotoxic and mutagenic.  Other sites that are mutagenic3 and are involved in base pair 
hydrogen bonding are O sites and N2 guanine.  When DNA-methylation occurs at N3 adenine, a 
cytotoxic nonmutagenic N3-methyladenine adduct is formed.  Therefore, compounds that can 
form N3-methyl adenine adducts would be a good choice of a DNA – damaging agent that can 
be used to cause only cell-death, and not lead to mutations which can cause secondary cancer. 
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Figure 2.  Structure and pairing of the bases: adenine with thymine and guanine with cytosine.  
The arrows indicate sites that can be alkylated by DNA-alkylating agents.  The N3-adenine site, 
which when methylated, results in cytotoxicity without leading to mutations, is highlighted in 
bold. 
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Targeting N3 adenine: 
 A compound that selectively produces only N3-methyladenine adducts, a methyl 
sulfonate ester tethered to N-methylpyrrolecarboxamide dipeptide (Me-Lex) has been described 
in literature, and is shown in Figure 3.  This compound has been shown to methylate adenines in 
the minor groove N3-site only in A/T rich regions2,4,5. Over 95% of the DNA-adducts formed by 
Me-Lex is N3-methyladenine.  Me-Lex thus has the desired ability to produce exclusively 
cytotoxic, non-mutagenic adducts. 
 The binding of Me-Lex in the minor groove of DNA at A/T rich regions is shown in 
Figure 4a and involves van der Waals forces, hydrogen bonding and electrostatics2.  The reason 
that this molecule binds selectively at A/T rich regions is because it is excluded from the minor 
groove at regions containing guanines due to the N2 of guanine that protrudes into the minor 
groove and sterically hinders such binding4.  Once Me-Lex binds in the minor groove at A/T rich 
regions, the reactive methyl group is transferred to the most nucleophilic site at A/T these 
regions, which is the N3 of adenine (Figure 4b).  After the methyl group is transferred the 
sulfonate ester is converted into a negatively charged sulfonate anion, which is repelled from the 
negatively charged DNA-backbone2.  N3-methyl adenine adducts formed by Me-Lex have been 
shown to be highly cytotoxic and nonmutagenic4.  Thus Me-Lex is a compound which, if 
targeted to breast cancer cells, can be used to destroy these cells without causing mutations. 
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Figure 3.  Structure of Me-Lex, the compound that produces N3-methyladenine adducts 
exclusively. 
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transfer of the reactive methyl group to N3-adenine. 
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Targeting breast cells: 
 Me-Lex can be targeted to breast cancer cells if it can be attached it to ligands, which 
are specific to breast cancer cells.  Estrogen receptors (ER) are over-expressed on breast cancer 
cells and expressed at low levels in normal breast cells6, and so ligands that target the ER can be 
used to target Me-Lex to these cells.  Thus, by using a compound like estradiol (Figure 5), which 
selectively binds to the ER, to deliver Me-Lex to breast cancer cells, one could preferentially 
target the alkylating agent to these cells. 
 The ER has a selective ability to detect estradiol and a high affinity to bind to 
estradiol7.  The ER’s ability to recognize estradiol is due to specific hydrogen bonding 
interaction and estradiol's non-polar character8.  The binding of estradiol to the ER causes a 
conformational change, which results in translocation of the estradiol-ER complex into the 
nucleus of the cell7,9.  Thus estradiol is an ideal candidate to deliver Me-Lex to the DNA in ER-
positive breast cancer cells. 
 It has been shown that modifications at the 7α, 11α, 16α, and 17β sites (Figure 5) do 
not radically affect the ability of estradiol to bind to the ER7,10,11.  Radiolabels and DNA 
alkylators have been attached to these sites and have been taken into the nucleus by the ER.  For 
example, a nitrogen mustard connected to estradiol at the 7α-position (Figure 6) has been shown 
to alkylate DNA in breast cancer cells at N7 of guanines10.  Therefore, this 7α-site is a good site 
to attach Me-Lex, a DNA-methylating agent, to estradiol, in order to deliver it to the DNA in 
breast cancer cells. 
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Figure 5.  Structure of estradiol, which selectively binds to the estrogen receptor (ER), which is 
over expressed in breast cancer cells.  The sites that can be modified on estradiol, without 
interfering with its binding to the ER, are 7α, 11α, 16α, and 17β. 
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Figure 6.  Structure of a large alkylating compound (nitrogen mustard) attached to the 7α 
position of estradiol that is know to alkylate DNA in ER-positive breast cancer cells. 
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Significance: 
 The goal of this research is to design and synthesize compounds that will methylate 
N3-adenine at A/T rich regions in the minor groove of DNA in breast cancer cells to form 
cytotoxic nonmutagenic adducts.  This will be achieved by connecting two compounds: Me-Lex, 
that produces cytotoxic N3 methyladenine lesions and estradiol, which targets breast cancer 
cells. Thus the overall design of the compounds is shown in Figure 7 and contains three 
segments: a DNA alkylating segment (Me-Lex), a cell-targeting segment (estradiol), and a linker 
segment.  The linker is very important to the design of the molecules and the length and 
composition of the linker will be varied in order to achieve optimum cell-targeting and DNA-
methylating properties. Also, the linker can be modified to vary the solubility of the compound 
in aqueous medium. 
 The purpose of making these compounds is to gain an understanding of the factors that 
govern the ability to deliver a selective DNA-alkylating agent to a specific kind of cell.  
Elucidation of these will pave the way for the design of new and improved cancer chemotherapy 
drugs that target only cancerous cells and minimize side effects. 
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Figure 7.  Overall design of compounds for this project includes three segments: a DNA 
alkylating segment, a cell-targeting segment, and a linker, which connects the two functional 
segments of the molecule. 
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SYNTHETIC STRATEGY 
 
 The design of the molecules for this project involve two main components: one is the 
DNA alkylating unit, which will alkylate DNA in a sequence specific minor at A/T rich regions, 
and the other is the cell-targeting unit that will target the DNA alkylating unit to breast cancer 
cells.  These two functional components have to be connected in the best possible way so that, 
after the connection, the DNA alkylating segment will still achieve its specific DNA alkylation, 
and the cell-targeting segment will also maintain its ability to target breast cancer cells.  Many 
different linker components, which will link the above two components, will have to be tested, in 
order to determine which of the linkers will result in the optimum properties. Therefore a good 
synthetic strategy would be one that will make it easy to introduce many different linkers 
efficiently. 
 Different linkers can be incorporated efficiently into the molecules if the DNA-
alkylating segment and the cell-targeting segment are first synthesized separately as appropriate 
intermediates, and then each of these components can be assembled together with the 
appropriately functionalized linker units at a late stage in the overall synthesis.  Figure 8 outlines 
this synthetic strategy that can be used to achieve these goals.  
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Figure 8.  Synthetic strategy used to prepare compounds that can target breast cancer cells and 
methylate N3-adenine in those cells. 
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Strategy for the synthesis of the DNA recognition component:  
 The component that is designed to achieve the selective DNA methylation has two 
functional units, one that recognizes the DNA minor groove at A/T rich regions, and the other is 
the methylating functionality, the methyl sulfonate.  Due to the reactive nature of the methyl 
sulfonate, it will have to be introduced at the very end of the overall synthesis, after all of the 
different units have been assembled together. 
 The over all synthetic strategy for the DNA recognition segment is outlined in Scheme 
1.  The commercially available N-methyl pyrrole can be converted into compound 1 by acylation 
with trichloroacetyl chloride.  This trichloroacetyl group is stable to aqueous hydrolysis, which 
eliminates the need for dry solvents in subsequent reactions.  Compound 1 can be nitrated at the 
4-position efficiently by using nitric acid and acetic anhydride to give compound 2.  The linker 
can be added to compound 2 by using ethyl β-alanine hydrochloride and triethylamine to give 
compound 3.  Then this nitro compound 3 can be coupled to compound 2 in order to give the 
dipeptide ester 4.  The ester group in 4 can be hydrolyzed to obtain a carboxylic acid, which can 
then be coupled to the appropriate cell-targeting component functionalized as an amine.    
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Scheme 1.  Outline for the synthetic strategy of the DNA recognition segment. 
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Strategy for the synthesis of the cell-targeting component: 
 The component that will enable the compounds to be targeted to breast cancer cells is 
estradiol because of its specific binding to the ER, which is over expressed in early stage breast 
cancer cells.  Therefore, the site on estradiol, at which the rest of the molecule will be connected, 
should be such that this connection does not interfere with its binding to the ER.  Several sites on 
estradiol have been used for attaching components without interfering with its ER-binding 
ability. Some of these sites are 7α, 11α, 16α, and 17β7,10,11.  One particular site, the 7α-site, has 
been used to attach a large alkylating component to estradiol (see Figure 6) and this compound 
was shown to successfully alkylate the DNA in breast cancer cells10.  Therefore, this site 
appeared to be a good choice for connecting the alkylating compound, Me-Lex, that is being 
used in this project. 
 It has been shown in literature that the tether which is used to connect different kinds of 
agents to estradiol at this 7α site has to be at least six-carbons in length for maintaining efficient 
binding to the ER12.  Tethers of up to eighteen carbons in length have been successfully used and 
in fact longer tethers have resulted in better binding to the ER13. The end of the tether must have 
a suitable functional group in order to facilitate connections to other units.  Functionalizing the 
end of the tether with an amine will make it easy to connect it to appropriate moieties ending 
with a carboxylic acid utilizing standard peptide coupling agents.  Based on all these 
considerations the compound shown in Figure 9 was selected as the cell-targeting segment. 
 
 
 The synthesis of this compound shown in Figure 9, starting from commercially 
available β-estradiol, has been described in literature14 -18.  The overall strategy that was utilized 
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is outlined in synthetic scheme 2.  In β-estradiol, the 7α-position to which the tether is to be 
connected is unreactive, and needs to be first converted into a reactive site.  This can be 
accomplished by introducing a ketone at the benzylic C-6 by first converting it into an alcohol, 
and then oxidizing the alcohol to the ketone.  In order to prevent interference form the 3-phenolic 
and 17-hydroxyl OH groups present on estradiol, they have to be first protected before this 
conversion can take place. 
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Scheme 2.  Outline for the synthesis of the cell-targeting segment.  
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 The presence of the ketone at the C-6 position renders the hydrogens at the 7-pos
acidic, and therefore the tether can now be introduced by using a base and the appropriate 
alkylating agent.  Trapping the enolate formed with triethyl borate before the addition of 6
iodohexene as the alkylating agent results in the introduction of the alkyl grroup at the α-
position.  The terminal alkene can then be converted into an alcohol by the anti-markovnikov 
addition of water across the double bond, and the alcohol can then be converted into the desired 
amine via the Mitsunobu reaction.  Thus the cell-targeting component, in the form of c
ition 
-
ompound 
 condensation with the DNA recognition component compound 5. 
n 
 
  
H, which will result in stronger binding to the 
e. 
ssembly
n 
14 is now ready for
Choice of Linker: 
 The linker unit can be varied to optimize the properties of the DNA recognition 
segment and cell-targeting segment.  Some examples of linkers that can be used are shown i
Figure 10.  The length of the alkyl chain in the linker can be varied to optimize the binding 
properties of both the DNA alkylating and cell-targeting segments.  If increase in water solubility
is required, then functional groups capable of hydrogen binding can be introduced in the linker.
A tertiary amine can be introduced into the linker if tighter binding to DNA is desired because 
the amine will get protonated at physiological p
negatively charged DNA backbon
A  of the Final molecule: 
 Assembly of the components will be achieved as outlined in Scheme 3. Once the 
individual components are prepared the DNA recognition component, which terminates with 
carboxylate group will be first hydrolyzed into a carboxylic acid, and then combined with the 
amine of the cell-targeting segment to give compound 15. The reactive methylsulfonate ester ca
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then be introduced as outlined in Scheme 4.  The nitro group on compound 15 is reduced
amine and then reacted with acryloyl chloride to give compound 16.  The alkene can be 
converted into the desired sulfonic acid 17 by the anti-Markovnikov addition of sodium bisulfi
The protecting groups on the estradiol will be removed before the methylation of the sulfonic 
acid to yield the final compound 18, in order to minimize the number of manipulations required
after the reactive methyl group is introduced.  The free OH groups on the estradiol unit are 
expected to interfere with the methylation of the sulfonic acid.  Ho
 to an 
te. 
 
not 
wever, if necessary, the 
 
uction of various linker units efficiently just before the assembly of 
e different components. 
 
protecting groups can be removed after the methylation reaction. 
 The synthetic procedure that has been outlined here will enable us to make the cell-
targeting component and the DNA sequence-recognizing component separately. This strategy is
also amenable to the introd
th
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Figure 10.  Examples of potential linkers with variations in length and composition.  
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Scheme 3.  Strategy for assembling the components. 
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Scheme 4.  Introduction of the reactive methylsulfonate ester into the molecule. 
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EXPERIMENTAL 
 
General 
 All solvents and reagents were purchased from VWR International (West Chester, 
Pennsylvania) or Sigma-Aldrich (Atlanta, Georgia) and were of the highest grade available 
unless otherwise noted.  Flash chromatography was performed with silica gel (230/400 mesh, 
Life Force Inc.).  All rotary evaporations were carried out using a Buchi R-3000 or a Buchi R-
114 rotary evaporator equipped with a Brinkmann model B-16 vacuum aspirator.  
Hydrogenations were performed using a Parr Hydrogenation Apparatus in a 500 mL Parr jar. 
Melting points were determined using a Mel-Temp II. 
 All anhydrous reactions were carried out in a fume hood, under a positive pressure of 
argon.  Glassware used for anhydrous reactions were dried overnight in an oven at 140°C, 
assembled while still hot, and cooled to room temperature under argon.  Solvents and reagents 
(liquids) for anhydrous reactions were obtained in bottles with sure-seal caps and transferred by 
using oven-dried glass syringes. 
 All 1H NMR and 13C NMR spectra were recorded with a Bruker 400 MHz NMR 
spectrometer, using CDCl3 or deuterated DMSO as the solvent.  CDCl3 was obtained from Alfa 
Aesar and the deuterated DMSO was obtained in sealed ampoules from ACROS Organics.  The 
spectra are reported in ppm and referenced to CDCl3 (7.24 ppm, 77 ppm) when acquired in 
CDCl3 and to DMSO (2.49 ppm, 39.5 ppm) when acquired with deuterated DMSO.  The samples 
were contained in 5 mm pyrex glass tubes obtained from Wilmad- LabGlass Buena, New Jersey. 
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 All TLC were performed on glass plates coated with silica gel (Whatman International, 
Maidstone, England, 150 A) that had a fluorescence indicator and were detected by UV 
visualization. 
Synthesis of DNA-methylating Component: 
  (4-nitro-2-trichloroacetyl-1-methyl pyrrole) (2).  To a cooled solution (-50 ºC) of 1 
(10.6 g, 46.7 mmol) in acetic anhydride (70 mL) was added fuming HNO3 (4 mL, 95.3 mmol) 
drop wise over 10 minutes.  The solution was allowed to stir at room temperature for 5 h, after 
which an ice bath was placed under the reaction flask.   Then distilled water (70 mL) was added 
and the reaction stirred overnight.  The precipitate that was formed was filtered to obtain the 
product 2 as a yellow-orange powder in a yield of 8.79 g (79%). mp = 122 - 128 °C, Rf = 0.87 
(ethyl acetate), 1H NMR (DMSO): δ 4.00 (s, 3H), 7.78 (d, 1H, J = 2 Hz), 8.56 (s, 1H).  13C NMR 
(DMSO): δ 95.02, 116.82, 121.08, 133.09, 134.73, 173.29. 
  (Ethyl β-(1-methyl-4-nitropyrrole-2-carboxamido) alanine) (3).  To a solution of 
ethyl β-alanine hydrochloride (4.9 g, 31.89 mmol) in ethyl acetate (150 mL) was added TEA (8.8 
mL, 63.14 mmol) and the mixture was stirred for 5 h at room temperature.  At this time a white 
precipitate will have formed.  Then 2 (10.86 g, 39.7 mmol) was added and the reaction was 
allowed to stir overnight.  The white precipitate was formed was removed by filtration.  The 
yellow crystals obtained upon solvent removal were recrystallized from 95% ethanol and water 
to give 3.7 g (43%) of 3 as a yellow crystal.  mp = 125 - 129°C, Rf = 0.60 (ethyl acetate), 1H 
NMR (DMSO): δ 1.16 (t, 3H, J = 7 Hz), 2.54 (t, 2H, J = 7 Hz), 3.39 (q, 2H, J = 7 Hz), 4.05 (q, 
2H, J = 7 Hz), 7.39 (d, 1H, J = 2 Hz), 8.11 (d, 1H, J = 2 Hz), 8.48 (t, 1H, J = 5 Hz).  13C NMR 
(DMSO): δ 14.53, 34.09, 35.40, 37.82, 60.43, 107.87, 125.98, 126.68, 134.20, 160.32, 171.65. 
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  (Ethyl β-[1-methyl-4-(1-methyl-4-nitroimidazole-2-carboxamido) pyrrole-2-
carboxamido] alaninate) (4).  To a solution of 3 (1.02 g, 3.8 mmol) in ethanol (25 mL) in a Parr 
jar was added Pd/C (0.10 g).  The reaction jar was then connected to the hydrogenator, flushed 
with H2 and evacuated twice, then filled with H2 to a pressure of 70 psi, and shaken, until TLC 
(ethyl acetate) indicated the complete disappearance of the starting material 4.  The reaction 
mixture was then filtered through celite to remove Pd/C and the Pd/C was washed thoroughly 
with ethanol.  The filtrate and washings were combined and the solvent was removed by rotary 
evaporation.  The residue was kept under vacuum for 30 minutes and then ethyl acetate (30 mL) 
was added to the residue, followed by the addition of 2 (1.02 g, 3.7 mmol).  This mixture was 
allowed to stir overnight upon which a yellow precipitate was formed.  The precipitate was then 
filtered to give 0.62 g (42%) of 4 as a yellow powder. The product was pure and no further 
purification was necessary. mp = 188 - 192°C, Rf = 0.53 (ethyl acetate), 1H NMR (DMSO): δ 
1.16 (t, 3H, J = 7 Hz), 2.53 (t, 2H, J = 7 Hz), 3.37 (q, 2H, J = 7 Hz), 3.78 (s, 3H), 3.94 (s, 3H), 
4.05 (q, 2H, J = 7 Hz), 6.82 (d, 1H, J= 2 Hz), 7.20 (d, 1H, J = 2Hz), 7.57 (d, 1H, J = 2 Hz), 8.10 
(t, 1H, J = 5 Hz), 8.16 (d, 1H, J = 2 Hz), 10.2 (s, 1H).  13C NMR (DMSO): δ 14.55, 34.46, 35.28, 
36.50, 37.94, 60.35, 104.57, 108.03, 118.56, 121.83, 123.42, 126.74, 128.68, 134.23, 157.30, 
161.63, 171.83. 
   (Ethyl β-[1-methyl-4-(1-methyl-4-nitroimidazole-2-carboxamido) pyrrole-2-
carboxamido] carboxylic acid)  (5).  To a solution of 4 (0.5 g, 1.3 mmol) in methanol was 
added a solution of KOH (0.46 g, 8.20 mmol) dissolved in 0.5 mL of deionized water.  The 
reaction was stirred overnight and then 10% HCl (1 mL) was added.  The reaction was allowed 
to stir overnight when a yellow precipitate fell out.  The precipitate was filtered out to give 0.41 
g (88%) of 5 as a yellow powder.  mp = 235 - 237°C, Rf = 0.14 (ethyl acetate),  1H NMR 
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(DMSO): δ 2.44 – 2.48 (m, 2H), 3.34 – 3.38 (m, 2H), 3.79 (s, 3H), 3.93 (s, 3H), 6.82 (d, 1H, J = 
2 Hz), 7.19 (d, 1H, J = 1 Hz), 7.55 (d, 1H, J = 2 Hz), 8.07 (t, 1H, J = 6 Hz), 8.17 (d, 1H, J = 1 
Hz), 10.22 (s, 1H), 12.17 (s, 1H).  13C NMR (DMSO): δ 34.47, 35.33, 36.52, 37.94, 96.19, 98.82, 
116.50, 121.81, 123.47, 126.13, 128.69, 133.31, 155.78, 161.61, 170.40. 
Synthesis of Estradiol Component: 
  (3,17β-Bis(2-tetrahydropyranyloxy)estra-1,3,5(10)triene) (6).  To a solution of β-
estradiol (10 g, 36.7 mmol) in CH2Cl2 (125 mL) was added dihydropyran (33 mL, 295.5 mmol) 
and then pyridinium ρ-toluenesulfonate (8 mg).  The reaction mixture was then equipped with a 
reflux condenser and was allowed to reflux for 3 hours while following by TLC.  The solvent 
was removed by rotary evaporation to give a yellow oil.  This yellow oil was purified by flash 
chromatography (5:1, hexane/EtOAc) to give a clear oil.  Ethanol was then added to the clear oil, 
the flask was then spun in a warm water bath until the oil dissolved and the ethanol turned white.  
Once this happened the flask was allowed to cool to room temperature upon which a white solid 
will start to fall out, then the flask was placed into the freezer overnight upon which a white solid 
precipitated.  The precipitate was then filtered off to give 13.05 g (80%) of 6 as a white solid.  
mp = 75 - 83°C, Rf = 0.42 (5:1, henaxe/EtOAc), 1H NMR (CDCl3): δ 2.82 (d, 2H, J = 4 Hz), 3.72 
– 3.94  (m, 1H), 4.64 – 4.68 (m, 1H), 5.38 (s, 1H), 6.77 (d, 1H, J = 2 Hz), 6.83 (d, 1H, J = 8 Hz), 
7.17 – 7.21 (m, 1H).  13C NMR (CDCl3): δ 19.20, 19.90, 19.92, 19.96, 23.07, 25.46, 25.56, 
25.67, 26.35, 27.25, 28.82, 29.81, 30.44, 31.14, 37.22, 37.80, 38.56, 42.85, 43.36, 44.02, 50.04, 
61.95, 62.79, 84.16, 86.65, 96.37, 99.44, 113.88, 116.45, 126.25, 133.71, 137.97, 154.84. 
  (3,17β-Bis(2-tetrahydropyranyloxy)estra-1,3,5(10)-triene-6-ol) (7).   To a cooled (-
78 °C) solution of 6 (7.0 g, 16 mmol) in THF (40 mL) was added 1.0 M potassium tert-butoxide 
(KOt-Bu) in THF (33.2 mL, 33.2 mmol), diisopropylamine (0.58 mL 4.10 mmol), and 1.6 M n-
   27 
 
BuLi in hexanes (19 mL, 30.4 mmol).  Upon addition of n-BuLi the reaction mixture turned dark 
red.  After 10 minutes trimethyl borate (4.4 mL, 38.75 mmol) was added and the reaction 
mixture turned yellow/orange.  After 5 minutes 35% H2O2 (20 mL) was added to the reaction, 
and a white solid forms.  Then after stirring the solid dissolves to give a clear light yellow liquid. 
The reaction mixture was allowed to stir at room temperature for 1 hour.  The organic phase was 
partitioned between toluene diluted with 10% HCl.  The organic layer was dried over MgSO4 
and filtered.  The solvent was removed by rotary evaporation and the product was purified by 
flash chromatography (2:1, hexane/EtOAc) to give 10.32 g (75%) of 7 as a white solid. mp = 73 
- 77°C, Rf  =0.34 (2:1, hexane/EtOAc), 1H NMR (CDCl3): δ 0.81 (d, 1H J = 7 Hz), 3.25 (q, 1H, J 
= 8 Hz), 4.64 – 4.68 (m, 1H), 4.79 – 4.85 (m, 1H), 5.44 (dt, 1H, J = 3 Hz), 6.95 (d, 1H, J = 6 Hz), 
7.18 – 7.22 (m, 1H), 7.29 (1H).  13C NMR (CDCl3): δ 11.72, 18.76, 18.80, 19.35, 19.89, 23.02, 
23.14, 25.26, 25.54, 25.64, 26.26, 27.19, 28.75, 30.37, 30.39, 31.07, 31.12, 37.08, 37.63, 37.88, 
37.93, 38.10, 38.21, 42.78, 43.28, 44.36, 44.49, 49.39, 49.51, 61.83, 61.99, 62.05, 62.73, 69.93, 
69.96, 70.00, 70.03, 84.03, 86.50, 96.20, 96.48, 96.61, 99.42, 114.78, 114.98, 115.70, 115.77, 
116.53, 126.27, 126.32, 133.43, 133.49, 133.55, 140.79, 140.84, 155.43, 155.52.  
  (3,17β-Bis(2-tetrahydropyranyloxy)estra-1,3,5(10)-triene-6-one) (8).  To a cooled 
(0 °C) solution of 7 (9.14 g, 20.0 mmol) in CH2Cl2 was added 2,2,6,6-Tetramethylpiperidine 1-
oxy (0.168 g, 1.1 mmol) and KBr (0.252 g, 2.12 mmol  in 8.4 mL of DI H2O).  14% Sodium 
hypochlorite (pH was adjusted to 8.5 by adding saturated NaHCO3) was added until a less polar 
compound was formed.  The organic phase was then washed with 10% sodium thiosulfate and 
deionized H2O.  The organic layer was dried over MgSO4 and gravity filtered.  The solvent was 
removed by rotary evaporation and the product was then purified by flash chromatography (3:1, 
hexane/EtOAc) to give 7.48 g (82%) of 8 as a white solid. mp = 48 - 60°C, Rf  = 0.71 (3:1, 
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hexane/EtOAc), 1H NMR (CDCl3): δ 0.81 (d, 3H, J = 6Hz), 2.73 (dd, 1H, J = 17 & 4 Hz), 3.69 – 
3.76 (m, 1H), 4.65 (dt, 1H, J = 17 Hz), 5.47 (q, 1H, J = 3 Hz), 7.21 (ddd, 1H, J = 1 Hz, 3 Hz, 8 
Hz), 7.33 – 7.36 (m, 1H), 7.71 (t, 1H, J = 3 Hz).  13C NMR (CDCl3) δ 11.56, 11.61, 18.78, 19.41, 
19.79, 22.81, 22.92, 25.16, 25.53, 25.63, 27.12, 28.86, 30.23, 31.03, 31.11, 36.71, 37.25, 39.82, 
39.85, 39.95, 42.65, 42.97, 43.02, 43.13, 44.12, 49.90, 50.04, 61.98, 62.15, 62.65, 83.87, 86.29, 
96.35, 96.39, 96.75, 99.40, 114.06, 122.53, 122.63, 126.48, 126.54, 133.46, 140.40, 140.51, 
197.90, 197.97.  
  (3,17β-Bis(2-tetrahydropyranyloxy)-7α-(5-hexen-1-yl)-estra-1,3,5(10)-triene-6-
one) (9).  To a solution of 8 (1.0 g, 2.20 mmol) in ethyl ether (10.5 mL) was added 1.0 M KOt-
Bu in THF (2.5 mL, 2.5 mmol).  After 10 minutes 1.0 M triethylborane (2.8 mL, 2.8 mmol) was 
added and the reaction mixture was stirred for 1 hour.  6-iodohexene (0.6g, 2.86 mmol) in ethyl 
ether was canulated into the reaction flask mixture.  After 30 minutes of stirring an equivalent 
amount of 1.0 M KOt-Bu in THF (2.5 mL, 2.5 mmol) was added and the reaction mixture was 
stirred overnight.  The reaction was then quenched with DI water and extracted with CH2Cl2.  
The organic layer was dried over MgSO4 and gravity filtered.  The solvent was removed by 
rotary evaporation and the product was purified by flash chromatography (5.5:0.5, 
hexane/EtOAc) to give 0.5 g (42%) of 9 as a white solid.  mp = 37 - 48°C, Rf = 0.17 (5.5:0.5, 
hexane/EtOAc), 1H NMR (CDCl3): δ 0.80 (d, 3H, J = 6 Hz), 2.31 – 2.40 (m, 1H), 2.46 (d, 1H, J 
= 11 Hz), 2.70 (t, 1H, J = 11 Hz), 3.75 (q, 1H, J = 8 Hz), 4.65 (dt, 1H, J = 15 Hz), 4.89 – 4.97 
(m, 2H), 5.47 (d, 1H, J = 3 Hz), 5.71 – 5.82 (m, 1H), 7.20 (d, 1H, J = 8 Hz), 7.30 – 7.33 (m, 1H), 
7.69 (t, 1H, J = 2 Hz).  13C NMR (CDCl3): δ 26.62, 26.81, 27.03, 28.62, 28.96, 29.72, 30.26, 
30.31, 33.63, 36.97, 37.41, 37.51, 42.25, 42.29, 42.37, 42.80, 43.28, 45.27, 45.36, 48.61, 48.69, 
61.95, 62.19, 62.32, 62.62, 83.90, 86.31, 96.33, 96.50, 96.70, 99.35, 114.35, 114.57, 114.66, 
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122.30, 122.36, 126.99, 127.03, 127.08, 132.27, 132.32, 138.84, 139.41, 139.54, 155.50, 155.56, 
200.84, 200.90. 
 (6-iodo-1-hexene).  To a solution of 5-hexen-1-ol (3.34g, 33.4 mmol) in a mixture of 
diethyl ether/acetonitrile (160/40 ml) was added triphenylphosphine (18g, 68.6 mmol) and 
imidazole (5g, 73.4 mmol).  Iodine (17 g, 66.9 mmol) was then added slowly to the reaction and 
the reaction was allowed to stir at room temperature until only one spot was seen by TLC.  
Diethyl ether (100ml) was then added and the reaction mixture was then filtered through celite.  
The filtrate was then washed with saturated sodium bicarbonate and brine, followed by a water 
wash.  The organic layer was then dried over Mg SO4 and gravity filtered.  The solvent was then 
removed by rotary evaporation and the product was purified by flash chromatography (hexanes) 
to give 6.10g (97%) of 6-iodo-1-hexene as a clear liquid.  1H NMR (CDCl3): δ 1.51 (m, 2H), 
1.84 (m, 2H), 2.08 (m, 2H), 3.19, (t, 2H, J = 7 Hz), 4.99 (m, 2H), 5.78 (m, 1H). 
  (7α-(5-hexen-1-yl)-estra-1,3,5(10)-triene-3,17β-diol) (10).  To a cooled (0 °C) 
solution of 9 (4.16 g, 7.8 mmol) in MeOH (186 mL) was added acetyl chloride (18.6 mL, 261.6 
mmol) in 1 mL aliquots.  The ice water bath was removed and the reaction was allowed to stir at 
room temperature for 30 minutes.  The solvent was removed by rotary evaporation to give a 
yellow oil.  To a cooled (0 °C) solution of the crude oil in CH2Cl2 (93 mL) was added 
triethylsilane (94 mL, 588.5 mmol) and Boron trifluoride diethyl etherate (96 mL, 777.8 mmol).  
The ice water bath was removed and the reaction solution was allowed to stir overnight.  20% 
K2CO3 (930 mL) was added resulting in a biphasic mixture. The biphasic mixture was then 
filtered through silica and to the filtrate was added CH2Cl2.   The organic layer was then dried 
over Mg SO4 and gravity filtered.  The solvent was then removed by rotary evaporation and the 
product was purified by flash chromatography (2:1, hexane/EtOAc) to give 2.36 g (85%) of 10 
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as a white solid. mp = 109 - 112°C, Rf = 0.24 (2:1,, 1H NMR (CDCl3): δ 0.78 (s, 3H), 2.30 (t, 
2H, J = 10 Hz), 2.72 (d, 1H, J = 16 Hz), 2.87 (dd, 1H, J = 17 & 5 Hz), 3.75 (t, 1H, J = 8 Hz), 
4.91 – 4.99 (m, 2H), 5.75 – 5.82 (m, 1H), 6.55 (d, 1H, J = 3 Hz), 6.62 (dd, 1H, J = 8 & 2 Hz), 
7.15 (d, 1H, J = 8 Hz).  13C NMR (CDCl3): δ 11.10, 14.21, 21.09, 22.67, 25.45, 27.28, 27.65, 
29.18, 30.56, 33.17, 33.87, 34.57, 36.88, 38.05, 41.95, 43.39, 46.47, 60.47, 82.06, 112.83, 
114.27, 116.13, 127.09, 131.92, 139.04, 153.38. 
  (3,17β-Bis(τ-butyldimethylsilanyloxy)-7α-(5-hexen-1-yl)-estra-1,3,5(10)-triene) 
(11).  To a cooled (0 °C) solution of imidazole (5 g) in DMF (76 mL) was added tertbutyl 
dimethylsilyl chloride  (5 g, 33.2 mmol).  The reaction was then stirred for 30 minutes and then a 
solution of 10 (2.43 g, 6.85 mmol) in DMF (11 mL) was added all at once.  The reaction was 
then stirred overnight and then was hydrolyzed with 0.1% K2CO3.  The reaction mixture was 
then extracted with CH2Cl2 and washed with deionized H2O.  The organic layer was dried over 
MgSO4 and gravity filtered.  The product was then purified by flash chromatography (2:1, 
hexane/EtOAc) to give 3.32 g (82%) of 11 as an oil.  1H NMR (CDCl3): δ 0.05 (d, 6H, J = 8 Hz), 
0.2 (s, 6H), 0.8 (s, 3H), 0.93 (s, 9H), 1.0 (s, 9H), 2.3 (t, 2H, J = 10 Hz), 2.7 (d, 1H, J = 17 Hz), 
2.85 (dd, 1H, J = 17 & 5 Hz), 3.67 (t, 1H, J = 8 Hz), 4.92 – 5.00 (m, 2H), 5.75 – 5.85 (m, 1H), 
6.55 (d, 1H, J = 2 Hz), 6.63 (dd, 1H, J = 8 & 2 Hz), 7.14 (d, 1H, J = 8 Hz).  13C NMR (CDCl3): δ 
-4.77, -4.45, -4.37, 1.03, 11.40, 14.14, 14.21, 18.13, 18.16, 22.71, 22.81, 25.39, 25.71, 27.31, 
27.65, 29.20, 29.38, 30.96, 31.94, 33.27, 33.86, 34.63, 37.39, 38.28, 41.96, 43.73, 46.13, 81.88, 
114.20, 117.17, 120.83, 126.68, 132.56, 136.82, 139.11, 153.23. 
  (3,17β-Bis(τ-butyldimethylsilanyloxy)-7α-(6-hydroxy-hexen-1-yl)-estra-1,3,5(10)-
triene) (12) .  To a solution of 11 (0.4663 g, 0.800 mmol) in THF (33 mL) was added 0.5 M 9-
borabicyclo[3.3.1]nonane in THF (10 mL, 5 mmol).  The reaction was then stirred overnight and 
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hydrolyzed with 3 M KOH (4.2 mL, 12.6 mmol).  After 5 minutes 30% H2O2 (4.2 mL) was 
added and the reaction was stirred for 3 hours. Saturated NaHCO3 (42 mL) was added and then 
extracted with CH2Cl2.  The organic layer was dried over MgSO4 and gravity filtered.  The 
solvent was removed by rotary evaporation and the product was then purified by flash 
chromatography (20%, EtOAc/hexane) to give 0.3477 g (72%) of 12 as a white solid. mp = 
55°C, Rf = 0.60 (20%, EtOAc/hexane), 1H NMR (CDCl3): δ 0.045 (d, 6H, J = 4 Hz), 0.199 (s, 
6H), 0.752 (s, 3H), 0.903 (s, 9H), 0.986 (s, 9H), 2.29 (t, 2H), 2.69 (d, 1H, J = 17 Hz), 2.85 (dd, 
1H, J = 17 & 6 Hz), 3.61 – 3.68 (m, 1H), 6.54 (d, 1H, J = 2 Hz), 6.64 (dd, 1H, J = 8 & 3 Hz), 
7.12 (d, 1H, J = 8 Hz).  13C NMR (CDCl3): δ - 4.76, - 4.44, - 4.36, 11.40, 18.14, 18.16, 22.82, 
25.71, 25.89, 29.80, 30.96, 32.81, 33.30, 34.63, 37.39, 38.29, 41.97, 43.73, 46.12, 63.05, 81.87, 
117.18, 120.83, 126.69, 132.58, 136.82, 153.22. 
  (3,17β-Bis(τ-butyldimethylsilanyloxy)-7α-(6-phthalimido-hexen-1-yl)-estra-
1,3,5(10)-triene) (13).  To a solution of triphenylphosphine (0.654 g, 2.23 mmol) in THF (22 
mL) was added diisopropyl azodicarboxylate (0.491 mL, 2.49 mmol) dropwise.  The reaction 
was allowed to stir for 40 mins and a white precipitate formed.  The phthalimide (0.366 g, 2.49 
mmol) was then added followed by 12 (0.500 g, 0.83 mmol).  The reaction was stirred at 0 °C for 
1 hour and then at room temperature overnight.  The solvent was removed by rotary evaporation 
and the product was then purified by flash chromatography (5% hexane/EtOAc) to give 0.5266 g 
(86%) of 13 as a yellow solid. mp = 58°C, Rf = 0.81 (5% hexane/EtOAc), 1H NMR (CDCl3): δ 
0.05 (d, 6H, J = 4 Hz), 0.199 (s, 6H), 0.74 (s, 3H), 0.9 (s, 9H), 0.98 (s, 9H), 2.27 (t, 2H, J = 10 
Hz), 2.68 (d, 1H, J = 17 Hz), 2.84 (dd, 1H, J = 17 and 5 Hz), 3.65 (t, 2H, J = 7 Hz), 5.23 – 5.28 
(m, 1H), 6.53 (d, 1H, J = 2 Hz), 2.61 (dd, 1H, J = 8 & 3 Hz), 7.11 (d, 1H, J = 8 Hz), 7.72 (q, 2H, 
J = 3 Hz), 7.84 (q, 2H, J = 3 Hz).  13C NMR (CDCl3): δ - 4.76, - 4.44, - 4.36, 11.39, 18.13, 18.15, 
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21.62, 22.80, 25.71, 25.89, 28.06, 28.62, 29.60, 30.94, 33.25, 34.57, 37.38, 38.07, 38.26, 41.95, 
43.72, 46.09, 81.86, 117.16, 120.82, 123.16, 126.67, 132.19, 132.55, 133.84, 136.80, 153.22, 
168.47. 
  (3,17β-Bis(τ-butyldimethylsilanyloxy)-7α-(6-phthalimido-hexen-1-yl)-estra-
1,3,5(10)-triene) (14).  To a solution of 13 (0.070 g, 0.096 mmol) in ethyl ether and EtOH was 
added anhydrous hydrazine (470 µL, 13.37 mmol) at room temperature in one installment.  The 
reaction mixture was then equipped with a reflux condenser and was refluxed for 2 hours.  
During this time a white solid formed on the walls and the solution turned a slight green/yellow.  
5% NaOH was added after the reaction cooled to dissolve the white solid.  After 30 minutes DI 
H2O was added and then was extracted with CH2Cl2.  The organic layer was dried over MgSO4 
and gravity filtered.  The solvent was then removed to give 0.053 g (91%) of 14 as a white solid.  
1H NMR (CDCl3): δ -0.013 (d, 6H, J = 4 Hz), 0.014 (s, 6H), 0.69 (s, 3H), 0.84 (s, 9H), 0.93 (s, 
9H), 2.21 (t, 2H), 2.65 (d, 2H), 2.79 (dd, 1H, J = 16 Hz), 3.60 (t, 1H, J = 8 Hz), 6.49 (d, 1H, J = 2 
Hz), 6.55 (dd, 1H, J = 8 & 2 Hz), 7.06 (d, 1H, J = 8 Hz). 13C NMR (CDCl3): δ - 4.75, - 4.43, - 
4.35, - 4.34, - 3.47, 1.04, 11.41, 18.06, 18.13, 18.16, 22.00, 22.83, 25.73, 25.90, 29.82, 29.86, 
30.97, 33.31, 33.69, 34.64, 37.40, 38.29, 41.99, 42.10, 43.73, 46.13, 81.88, 113.25, 116.51, 
117.18, 120.84, 126.70, 126.87, 130.75, 132.57, 136.82, 136.86, 153.22, 154.98. 
Synthesis of coupling DNA recognition and cell targeting segments: 
2-{[5-({[5-({[3-({6-[(7β,8ξ,9ξ,13α,14ξ,17α)-3,17-bis{[tert-
butyl(dimethyl)silyl]oxy}estra-1,3,5(10)-trien-7-yl]-1-hexyl} amino)-3-
oxopropyl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]amino}carbonyl)-1-methyl-1H-
pyrrol-3-yl]amino}-2-nitro (15).  To a dry flask under argon was added 23 (0.032g, 0.0882 
mmol) and 17 (0.053g, 0.08804 mmol).  Then 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide 
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hydrochloride (0.023g, 0.1315 mmol), 4-Dimethylaminopyridine (0.027g, 0.221 mmol), 1-
Hydroxybenzotriazole hydrate (0.041g, 0.2678 mmol), and CuCl2 (0.0012g, 0.0089 mmol) was 
added to the flask.  Once all the solids were added DMF (1 mL) was added and the reaction 
solution was stirred until TLC showed that the reaction was complete.  The reaction mixture was 
then washed with CH2Cl2 then NaHCO3, HCl, and finally NaCl.  The organic layer was then 
dried over MgSO4 and filtered.  The solvent was removed by rotary evaporation and the product 
was then purified by flash chromatography (3:1.5 Ethyl Acetate/Hexane) to give 0.0288g 
(34.5%) of 18 as a yellow solid.  1H NMR (CDCl3): δ 0.023 (d, 6H, J = 4 Hz), 0.18 (s, 6H), 0.73 
(s, 3H), 0.89 (s, 10H), 0.97 (s, 10H), 2.47 (t, 2H, J = 6 Hz),  2.65 (d, 1H, J = 16 Hz), 2.85 (dd, 
1H, J = 17 & 5 Hz), 3.25 (q, 2H, J = 7 & 13 Hz), 3.65 (m, 3H), 3.86 (s, 3H), 4.03 (s, 3H), 6.38 (s, 
1H), 6.4 (d, 1H, J = 2 Hz), 6.53 (d, 1H, J = 2 Hz), 6.6 (dd, 1H, J = 2 & 8 Hz), 2.72 (t, 1H, J = 6 
Hz), 7.1 (d, 1H, J = 8 Hz), 7.3 (d, 1H, J = 2 Hz), 7.55 (d, 2H, J = 18 Hz), 9.00 (s, 1H).  13C NMR 
(CDCl3):  δ -4.81, -4.49, -4.41, -4.40, 11.35, 18.07, 18.10, 22.77, 25.66, 25.83, 28.11, 29.46, 
29.70, 30.91, 33.26, 34.55, 35.45, 35.68, 36.55, 37.32, 38.12, 38.23, 39.74, 41.90, 43.68, 46.06, 
81.79, 103.34, 107.68, 117.17, 119.35, 120.79, 121.08, 123.32, 126.17, 126.71, 126.96, 132.56, 
134.96, 136.74, 153.16, 157.67, 161.83, 171.81. 
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RESULTS AND DISCUSSION 
 
 The overall goal of this project was to make compounds that alkylate the N3 adenine of 
DNA in the minor groove at A/T rich regions in breast cancer cells.  In order to do this our tactic 
was to combine a specific DNA methylating agent with a cell-targeting agent with appropriate 
linkers. The linkers have to be optimized in order to achieve the best properties of cell targeting 
and DNA methylation.  Therefore it was realized early on that numerous molecules with various 
linkers will have to be made and then tested to see what effect the linker variations have on the 
DNA methylation and cell targeting abilities of these molecules.  Thus a modular design was 
developed that would allow the DNA recognition and cell-targeting components to be 
synthesized separately with appropriate functional groups so that they can be later assembled 
very quickly with different linker units.   
 Based on consideration of raw materials available and the design constraints it was 
decided that compounds 5 and 14 shown in Figure 11 would be made.  The DNA recognition 
component was synthesized as a nitro carboxylic acid without the reactive methylsulfonate and 
the cell-targeting component was synthesized with an amine at the end so that it can be 
connected to appropriate carboxylic acids.   
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 Once the linker units to be used, containing an amine at one end and an ester at the 
other end, are identified, the amine will first be reacted with the carboxylic acid of the DNA 
recognition component.  After the formation of this amide bond, the ester at the other end will be 
hydrolyzed into a carboxylic acid, which will then be coupled with the amine of the cell-
targeting component.  Once the units are assembled, the DNA recognition component can be 
converted into the methylating compound by introducing a methylsulfonate ester, which has the 
reactive methyl group that will be transferred to the DNA. 
 In this project the DNA recognition component was synthesized as the compound 
shown in Figure 12.  Details of the synthesis of this component are given in the experimental 
section and an outline can be seen in Scheme 5 below.  While the addition of the linker unit has 
been accomplished in the second step of this synthesis following methods described in 
literature19, it is possible to attach this unit to the dipyrrole later on in the synthetic scheme. 
 The nitro pyrrole 2 was obtained by nitration of pyrrole 1 using fuming nitric acid in 
acetic anhydride at –40 oC.  Upon completion of the reaction, an excess of water is added to 
convert all the acetic anhydride into acetic acid, in which the desired product has lower solubility 
than the starting material. Therefore, the product falls out of solution and can simply be isolated 
by simple filtration.  A small amount of the undesired 5-nitro isomer is detected by NMR, but the 
5-nitro can be separated from the 4-nitro by their difference in solubility since the 5-nitro is more 
soluble in acetic acid.  On occasion, when the acetic acid is diluted with an excessive amount of 
water, both isomers precipitate.  Therefore, careful dilution of acetic anhydride with water results 
in the precipitation of only the desired 4-nitro compound 2.   
 
 
   36 
 
 
 
TBSO
OTBSH2N
N
NH
N
H
N
O
NO2
O
DNA Recognition
Component
14
Cell Targeting 
Component
OH
O
Linker
5
 
Figure 11.  Structure of the DNA recognition with the linker attached and cell targeting 
components.  
 
 
N
Figure 12.  Structure of the DNA recogn
N
NH
N
H
N
OEtO
O
NO2
O
N
O2N
N CCl3
O
HNO3
Acetic Anhydride
DI H2O
79%
1. KOH
2. HCl
80%
4
 
 
 
NH
N
H
N O
NO2
O
O OH  
ition compound that was actually made. 
N
O2N
H
N
O OEt
O
CCl3
O
N
O2N
CCl3
O
EtOH
Ethyl Acetate
ethyl beta -alanine hydrochloride
TEA
Ethyl Acetate
43%
1. Pd/C, H2
2.
42%
N
NH
N
H
N
OHO
O
NO2
O
2 3
5  
  37 
Scheme 5.  Synthesis of the DNA recognition component. 
  The trichloro group in compound 1 is stable to aqueous hydrolysis; however, it reacts 
very efficiently with amines.  This enables the subsequent coupling reaction to be performed 
without the use of dry solvents, which would be required if acid chlorides were used to achieve 
the coupling.  Also, upon reaction with an amine, the trichloro group is converted to chloroform, 
which can be easily removed by rotary evaporation. 
 The linker (scheme 5) is obtained as the hydrochloride salt of the amine, and the free 
amine is then generated, in situ, by using triethylamine as a scavenger of HCl.  As the free amine 
is generated, it reacts with the trichloro compound to form the peptide linkage to give the nitro 
pyrrole ester 3.  Compound 3 can be further purified through recrystalization from ethanol. 
 The nitro compound 3 was hydrogenated under high pressure in order to obtain the 
amine.  The amine is sensitive to air oxidation and has to be coupled to compound 2 immediately 
in order to obtain dipeptide ester compound 4.   
 The ester of compound 4 can be easily hydrolyzed to the carboxylic acid of 5 and then 
can be used to couple with the cell-targeting segment, which will be in the form of an amine.  
The yields for each step in the synthesis of these compounds are summarized in Table 1 below.  
The overall yield of scheme 6 is 11%.  Some improvements can be made particularly to the 
reaction that gives the dipeptide ester compound 4 by bubbling argon through the solution so that 
air oxidation could have been minimized.  This was not attempted because starting materials for 
this part of the synthesis were inexpensive and large quantities were easily obtained.  Now that 
the synthesis of the DNA recognition component is complete, it is now ready to be coupled to the 
cell-targeting component.                    
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Table 1.  Percent yields for the compounds in the synthesis of the DNA recognition component. 
 
 
 
 
 
 
 
 
 
 
 
 In this project the cell-targeting component 14 was synthesized as the compound 
shown below in scheme 6.  The synthesis of the cell-targeting component has been described in 
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literature in different ways.  The procedures that were used were adapted from the literature to 
achieve the synthesis that was used and these procedures have been described in the 
experimental section and are outlined in scheme 6.  
  As was discussed earlier, before functionalizing the benzylic position the –OH groups 
have to first be protected and the procedure described in literature used dihydropyran14.  
However the use of dihydropyran as the protecting group leads to problems in the 
characterization of compound 6 using 13C NMR because there are more carbons in the NMR 
than in the compound.  This problem is due to the mixture of diastereoisomers as a result of an 
asymmetric center that is formed during the addition of the dihydropyran protecting groups20.  
The proton NMR of protected compound 6 was compared to the spectrum given in the literature 
of the synthesis that was followed.  Also the proton NMR spectra of the subsequent steps had the 
expected changes showing that the protected compound 6 was formed.     
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Scheme 6.  Synthesis of the cell-targeting component. 
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 All descriptions of compound 6 in literature reveal it to be a viscous oil and we 
obtained an oil after the work up of 6.  The actual yield obtained was much larger than the 
theoretical yield and when placed under prolonged vacuum a decrease in weight was noticed.  
This analysis showed that a significant amount of this oil was solvent and despite extensive 
evacuation not all of the solvent was removed from this viscous oil.  Since we could not quantify 
the proportion of the mixture that was solvent, calculations of the appropriate quantities for the 
subsequent steps were very difficult.  Therefore we under took further efforts to better purify this 
compound 6 and for the very first time we succeeded in crystallizing this compound as a solid by 
using ethanol.  Numerous attempts were taken to recrystallize protected compound 6 and it was 
found that recrystallization at low temperatures worked best.            
 Protected ketone compound 8 is obtained through a two-step procedure by converting 
protected estradiol 6 into protected alcohol compound 715.  Then the alcohol of 7 is converted 
into the ketone of 8.  The alcohol in compound 7 is a mixture of two isomers but this does not 
matter because the alcohol is oxidized into ketone.  Initially pyridinium chlorochromate (PCC) 
was used to convert the alcohol of 7 into the ketone of 814 however high yields were not obtained 
because the compound stuck to the PCC.  Therefore we followed a different procedure that used 
sodium hypochlorite and TEMPO, which gave much-improved yields16. 
   6-iodo-1-hexene was used to introduce the 6-carbon tether to the 7α position of 
compound 8 but 6-iodo-1-hexene is not commercially available.  Initially 6-iodo-1-hexene was 
obtained by reacting 6-bromo-1-hexene with NaI17 but due to incomplete conversion of 6-bromo 
into 6-iodo there was a mixture of the two compounds.  The two compounds are so similar in 
polarity that they cannot be separated by column chromatography.  Furthermore 6-bromo-1-
hexene was expensive; therefore, an alternate procedure was used in which 5-hexen-1-ol18 is 
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converted into 6-Iodo-1-hexene by reacting imidazole, triphenylphosphine, and iodine.  5-hexen-
1-ol is less expensive than the previous compound 6-bromo-1-hexene.  Using this procedure we 
were able to obtain 6-iodo-1-hexene in better yields.  Also due to the large difference in polarity 
between the product alkene and the starting alcohol, they can be easily separated by using 
column chromatography.  
 In order to attach 6-carbon tether to the 7α position of 8 the enolate is first generated by 
using potassium tertbutoxide.  Then triethyl borane is used to trap the enolate to prevent O-
alkylation and then water is added in order to quench the reaction17.    The TLC showed that only 
one compound was formed which was confirmed by NMR.  When comparing the NMR obtained 
and the NMR in literature all peaks matched up.  This evidence shows that this reaction produces 
only compound 9.  The yield of 9 is only 42% however unreacted starting material from this 
reaction can be recovered and the adjusted yield is 60%.    
 The next step is to reduce the ketone of 9 to give compound 10.  It was shown in the 
literature that the protecting groups should be removed first to give better yields.  Thus the 
procedure that was used removed the protecting group first by using acetyl chloride and 
methanol16.  Then the ketone was reduced by using Et3SiH and BF3Et2 to give compound 10.  
The alcohol groups on 10 were then reprotected with tertbutyl dimethylsilyl (TBS) to give 
protected compound 1117. 
 The terminal alkene of compound 11 was then converted into the terminal alcohol of 
compound 12 by the anti-Markovnikov addition of water using 9-BBN and H2O217.  The terminal 
alcohol of 12 can be converted into the phthalimide of 13 by using Mitsunobo conditions17.  The 
conversion of the phthalimide of 13 into the amine of 14 is very efficient and can be achieved in 
yields greater than 90%17.  Thus the amine compound 14 can be stored as the phthalimide 13 to 
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avoid any possible decomposition.  The synthesis of the cell-targeting component is complete 
and it is now ready to be coupled to the linker. 
 The next step was to put together compound 5 and compound 14 to form compound 15.  
Compound 15 has both the DNA recognition and the cell-targeting components connected 
together to form one compound that could now potentially alkylate DNA in breast cancer cells.  
The details of this coupling reaction are found in the experimental chapter and are outlined in 
scheme 7.  Thus for the first time we have succeeded in assembling a DNA recognition segment 
with a cell-targeting segment with a certain linker.   
 Further efforts are on-going in the laboratory to convert the nitro into the 
methylsulfonate ester (scheme 8).  This conversion involves the reaction of the nitro group into 
the amine immediately followed by the condensation of the amine with acryloyl chloride to make 
the olefin.   The olefin will then be reacted with sodium bisulfite to give the sulfonic acid.  The 
sulfonic acid will then be converted into the methylsulfonate ester upon reaction with 3-methyl-
p-toyltriazine to give the final compound 18.           
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Scheme 7.  Synthetic strategy for coupling the DNA recognition and cell targeting components. 
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Scheme 8.  The strategy for conversion of the nitro into the methylsulfonate ester. 
  
 
 
 In this project we have succeeded in assembling together a DNA recognition 
component and a cell-targeting component into a single molecule, and developed an efficient 
synthetic procedure that is amendable to the synthesis of many different compounds varying in 
composition of the linker.  Studies in the laboratory have shown that various linkers with 
different lengths can be added to the carboxylic acid end of the DNA recognition component 
shown in figure 13.  Therefore we have developed a procedure that can be used to easily 
assemble multiple components in order to make numerous compounds.   
 Once the methylating compounds are made, there are two different properties that have 
to be evaluated, one is the cell targeting ability and the other is the ability to form N3 
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methyladenine adducts.  In future studies, experiments will be conducted to determine the DNA 
methylating ability by conducting HPLC experiments.  The compound will be reacted with 
genomic DNA and the methylated bases will be isolated, characterized, and quantified by using 
HPLC methods.  Chemical sequencing analysis and gel electrophoresis will be used to determine 
at what sequence the methylation of the bases occurs.  These experiments will verify if the DNA 
recognition component still methylates DNA in the minor groove at A/T rich regions at the N3 
adenine.  These results from the methylation studies will be correlated to the structure and 
composition of the linker.  Cells that do and do not express the estrogen receptor will be used to 
test the cell targeting ability of these compounds.  The cells will be exposed to the N3-methyl 
adenine forming compounds and if targeting is achieved then the compounds will be more toxic 
to cells that express the ER.                       
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CONCLUSION 
 
 The main goal of this project was to make a new compound by coupling a DNA 
recognition component and a cell-targeting component.  The other goal was to develop a 
synthetic strategy that will allow easy variation in the mode of connection of the above two 
components.  In this project, for the very first time, we have managed to make a compound that 
has a DNA recognition component and a cell-targeting component in a single molecule.  This 
compound is three steps away from being converted into the desired methylating compound, 
which can be tested for its DNA-methylating and breast cancer cell-targeting properties.  We 
have also succeed in developing a modular synthetic strategy in which the two different 
functional components – the DNA recognizing unit and the breast cancer cell-targeting unit – are 
synthesized separately, and can then be assembled together with varying linking units as desired. 
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APPENDIX B 
Abbreviations 
Deoxyribosenucleic acid......................................................................................DNA 
Adenine ..............................................................................................................A 
Thymine ..............................................................................................................T 
Guanine ..............................................................................................................G 
Cytosine ..............................................................................................................C 
Estrogen Receptor................................................................................................ER 
Deuterated Chloroform………………………………………………………….CDCl3
Dimethyl Sulfoxide..............................................................................................DMSO 
Melting Point……………………………………………………………………mp 
Tetrahydrofuran…………………………………………………………………THF 
Tertbutyl dimethylsilyl.........................................................................................TBS 
Tetrahydropyranyl................................................................................................THP 
Potassium tert-butoxide .......................................................................................KOt-Bu 
Retention Factor...................................................................................................Rf 
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